Status:

COMPLETED

Usability, Safety and Efficacy of AspivixTM

Lead Sponsor:

Aspivix SA

Conditions:

IUD Insertion

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD). Currently, the available instruments are t...

Eligibility Criteria

Inclusion

  • Participants older than 18 years
  • Participants presenting at the outpatient clinic for Mirena IUD insertion.
  • Participants able to provide informed consent as documented by signature with at least 24 hours of reflection time
  • Good understanding of written and oral speaking used at the centre where the study will be carried out.

Exclusion

  • Participants who are contraindicated for the insertion of the IUD Mirena
  • Participants under use of excessive alcohol, narcotics or benzodiazepines prior to procedure
  • Participants who do not wish to be informed of a chance discovery
  • Participant receiving anaesthetics prior to IUD insertion procedure
  • Participants on anticoagulant medication
  • Participants under use of an analgesic
  • Previous cervical operation
  • Severe vaginal bleeding
  • Participant previously enrolled in this study
  • Cervix diameter smaller than 26 mm
  • Mullerian anomalies with two cervices
  • Nabothian cyst
  • Cervical myomas
  • Cervical condylomas
  • Squamous intraepithelial lesion (Cervical dysplasia)
  • Cervical endometriosis
  • Cervical tears
  • A well exposed cervix and / or well aligned vaginal and cervical canals where no traction is required for IUD insertion
  • Other cervical abnormalities (cervical polyp, cervical lesion, or irregularity) which may contraindicate or complicate IUD insertion
  • Large ectopy, for which it is not possible to find a suitable location near the ectopy where native tissue is present
  • Large scar tissue, for which it is not possible to find a suitable location near the scar where native tissue is present

Key Trial Info

Start Date :

July 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 2 2020

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT04441333

Start Date

July 1 2020

End Date

December 2 2020

Last Update

December 11 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department Women, Mother & Child, University Hospital

Lausanne, Canton of Vaud, Switzerland, 1011

Usability, Safety and Efficacy of AspivixTM | DecenTrialz